Compare Adaptive Biotechnologies Corp (ADPT) vs Abercrombie & Fitch Co. (ANF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Abercrombie & Fitch Co. — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Abercrombie & Fitch Co. trades at $86.21 (market cap $3.96B). The key difference: Abercrombie & Fitch Co. is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ADPT | ANF | |
|---|---|---|
Market Cap | $3.33B | $3.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $129.85 |
52-Week Low | $10.24 | $65.61 |
Enterprise Value | $3.19B | $4.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ANF trades at $89.07, down 3.61% today but maintains strong fundamentals with a P/E of 8.68 and robust profitability metrics including 39.04% ROE. The stock shows technical bullish signals with support at $88 and resistance at $92. Recent earnings beats and 2025 revenue growth to $4.95B demonstrate operational strength, while expansion into third-party footwear and Target partnerships highlight growth initiatives.
ANF presents a compelling value opportunity with attractive valuation multiples and consistent earnings outperformance. Key risks include moderating sales growth and international market softness. Analyst consensus price target of $107.71 suggests 21% upside potential, supported by strong institutional sentiment despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →
